Bosutinib‐Associated Cardiac Tamponade: Late‐Onset Treatment‐Emergent Adverse Event—A Case Report
Open Access
- 1 January 2026
- journal article
- case report
- Published by Wiley in Case Reports in Cardiology
- Vol. 2026 (1)
Abstract
Fluid retention due to tyrosine kinase inhibitor administration might lead to pericardial effusion and right heart failure. Here, we present the case of a 63‐year‐old man with subacute cardiac tamponade complicated with heart failure, acute kidney injury, and generalized edema due to the bosutinib treatment.Keywords
This publication has 15 references indexed in Scilit:
- European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemiaLeukemia, 2020
- Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel reviewJournal of Hematology & Oncology, 2018
- Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE TrialJournal of Clinical Oncology, 2018
- Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid LeukemiaJournal of Clinical Oncology, 2015
- 2015 ESC Guidelines for the diagnosis and management of pericardial diseasesEuropean Heart Journal, 2015
- Bosutinib versus imatinib in newly diagnosed chronic‐phase chronic myeloid leukaemia: results from the 24‐month follow‐up of the BELA trialBritish Journal of Haematology, 2014
- The regulatory crosstalk between kinases and proteases in cancerNature Reviews Cancer, 2010
- Targeting cancer with small molecule kinase inhibitorsNature Reviews Cancer, 2009
- Corticosteroids for Recurrent PericarditisCirculation, 2008
- A method for estimating the probability of adverse drug reactionsClinical Pharmacology & Therapeutics, 1981